

PLATYPUS TECHNOLOGIES

October 4, 2010

Bringing Science to the Surface™

Platypus Technologies, LLC
5520 Nobel Drive, Suite 100
Madison, WI 53711

Next Generation Oris™ Pro 384 Cell Migration Assay

Madison, WI – Platypus Technologies announces the introduction of the first of a new generation of cell motility assays designed specifically for fully automated high throughput screening (HTS) utilizing high content screening (HCS) and high content imaging (HCI) systems. The new Oris™ Pro 384 Cell Migration Assay – Tissue Culture Treated uses a non-toxic biocompatible gel (BCG) to form a centrally located and temporary cell-free zone on cell culture surfaces in a 384-well format. After cell seeding the BCG dissolves to reveal a detection zone into which the migration of cells can be observed either in real time or after further experimental processing. This breakthrough product enables researchers to capture and quantify cell migration data while substantially improving assay efficiency and dramatically reducing assay costs.

Measurement of cell migration is an example of phenotypic cell analysis that enables researchers to better understand the impact of candidate therapeutic compounds on biological pathways and cellular behavior. The new Oris™ Pro 384 well format is compatible with HTS, HCS and HCI systems that are already available in cell biology laboratories. This next generation product will play an important role in accelerating the development of new therapeutics for wound healing, cancer treatment and other diseases impacted by the movement of cells. Additional information about this product is available at: <http://www.platpustech.com/orispro384.html>



About Platypus Technologies, LLC:

Platypus Technologies, LLC develops innovative products for the analytical and life sciences that utilize recent advances in nanotechnology and materials science. Platypus Technologies has successfully launched the Oris™ cell-based assay products that enable life science researchers to study cell migration; a process critical to understanding wound healing, cancer and other biological functions. The Company is also developing a range of products, for industrial, security, diagnostic and environmental applications based on its proprietary platform technology utilizing liquid crystals for the rapid and low-cost detection of molecular interactions.

For more information: Richard S. Schifreen, Ph.D.
President & CEO
Ph: 608.237.1274
rschifreen@platpustech.com



Platypus Technologies, LLC
www.platpustech.com

5520 Nobel Drive, Suite 100
Madison WI 53711 USA

Toll Free: 866.296.4455
Fax: 608.237.1271